Methods for determining the risk of prenatal complications
AssigneesPerkinElmer Health Sciences, Inc., Wallac Oy, The Fetal Medicine Foundation
InventorsHoward Cuckle, Kypros Nicolaides, Tarja Ahola, Leona Poon
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
Claims35
A method for determining the risk of pre-eclampsia in a pregnant individual, comprising:
- determining the amount of one or more biochemical markers selected from placental growth factor (P1GF) and pregnancy-associated plasma protein A (PAPP-A) in one or more blood samples from the individual;
- determining the blood pressure of the individual;
- and determining the risk of pre-eclampsia using the amount of each of the selected one or more biochemical markers and the blood pressure of the individual.
A medical profile for a pregnant individual, comprising information for determining the risk of pre-eclampsia in the individual, the information comprising the amounts of one or more biochemical markers present in one or more blood samples from the individual, the biochemical markers selected from placental growth factor (P1GF) and pregnancy-associated plasma protein A (PAPP-A);
- and the blood pressure of the individual, wherein the medical profile is stored on a computer-readable medium.
An apparatus for determining the risk of pre-eclampsia in a pregnant individual, comprising:
- a data input means for inputting the amounts of one or more biochemical markers selected from placental growth factor (P1GF) and pregnancy-associated plasma protein A (PAPP-A) in one or more blood samples from the individual, and the blood pressure of the individual;
- and
- a calculation means for determining the risk of developing pre-eclampsia using the input amounts of the biochemical markers and the blood pressure.
A method for determining the risk of a chromosomal abnormality in a fetus, comprising:
- determining the amount of placental growth factor (P1GF), pregnancy-associated plasma protein A (PAPP-A) and free human chorionic gonadotropin (free beta hCG) in one or more blood samples taken from a pregnant individual;
- and determining the risk of the chromosomal abnormality in the fetus using the measured amounts of P1GF, PAPP-A, and free beta hCG.
A medical profile for a pregnant individual, comprising information for determining risk of a chromosomal abnormality in a fetus, wherein the information comprises the amounts of P1GF, PAPP-A, and free beta hCG in one or more blood samples from the pregnant individual, and wherein the medical profile is stored on a computer-readable medium.
An apparatus for determining risk of a chromosomal abnormality in a fetus, the apparatus comprising:
- a data input means for inputting the amounts of P1GF, PAPP-A, and free beta hCG in one or more blood samples obtained from a pregnant individual;
- and
- a calculation means for determining the risk of a chromosomal abnormality in a fetus using the amounts of the P1GF, PAPP-A, and free beta hCG.
Dependencies are inferred from the claim text.